Propagation of venous thrombi or rethrombosis after coronary thrombolytic therapy can occur despite heparin administration. To explore potential mechanisms, we set out to determine whether clot-bound thrombin is relatively protected from inhibition by heparin-antithrombin III 
Introduction
Propagation of venous thrombi or rethrombosis after coronary thrombolytic therapy can occur despite heparin administration. To explore potential mechanisms, we set out to determine whether clot-bound thrombin is relatively protected from inhibition by heparin-antithrombin III but susceptible to inactivation by antithrombin III-independent inhibitors. Using plasma fibrinopeptide A (FPA) levels as an index of thrombin activity, we compared the ability of thrombin inhibitors to block FPA release mediated by fluid-phase thrombin with their activity against the clot-bound enzyme. Incubation of thrombin with citrated plasma results in concentration-dependent FPA generation, which reaches a plateau within minutes. In contrast, there is progressive FPA generation when fibrin clots are incubated with citrated plasma. Heparin, hirudin, hirudin dodecapeptide (hirugen), and D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone (PPACK) produce concentration-dependent inhibition of FPA release mediated by fluid-phase thrombin. However, heparin is much less effective at inhibiting thrombin bound to fibrin because a 20-fold higher concentration is necessary to block 70% of the activity of the clot-bound enzyme than is required for equivalent inhibition of fluid-phase thrombin (2.0 and 0.1 U/ml, respectively). In contrast, hirugen and PPACK are equally effective inhibitors of fluid-and solidphase thrombin, while hirudin is only 50% as effective against the clot-bound enzyme. None of the inhibitors displace bound "SI-labeled thrombin from the clot. These studies indicate that (a) clot-bound thrombin is relatively protected from inhibition by heparin, possibly because the heparin binding site on thrombin is inaccessible when the enzyme is bound to fibrin, and (b) clot-bound thrombin is susceptible to inactivation by antithrombin III-independent inhibitors because the sites of their interaction are not masked by thrombin binding to fibrin. For these reasons, antithrombin III-independent inhibitors may be more effective than heparin in certain clinical settings.
(J. Clin. Invest. 1990 . 86:385-391.) Key words: thrombin.
fibrin -heparin -antithrombin III Thrombin converts fibrinogen into insoluble fibrin by cleaving fibrinopeptides A and B (FPA and FPB, respectively)' from the amino-terminal regions ofthe Aa and B(B chains of fibrinogen, respectively (1) . During this reaction thrombin is adsorbed to fibrin through a site distinct from its catalytic serine center (2) (3) (4) (5) (6) (7) . Since thrombin bound to fibrin equilibrates slowly with the external solution (3), its reactivity with inhibitors outside the clot may be limited.
Heparin is an effective antithrombotic agent that acts primarily by catalyzing the inactivation of thrombin and activated Factor X by antithrombin III (8) (9) (10) (11) (19) or in man (20) .
The limitations of heparin therapy are consistent with the hypothesis that in a plasma system, thrombin bound to fibrin is protected from inactivation by heparin-antithrombin III. Accordingly, we have performed studies in plasma to determine whether thrombin bound to fibrin is (a) enzymatically active, (b) relatively resistant to inhibition by heparin-antithrombin III, and (c) more (21) .
Radioimmunoassay of FPA. FPA was assayed as previously de- scribed (22) using antiserum R2. This antibody is specific for FPA (23, 24) and does not crossreact with fibrinogen or FPA-containingfragments derived from the amino-terminal region of the Aa chain of fibrinogen (24) (25) (26) (29) . The '25I-labeled thrombin had a sp act of -5.4 X 1044,Ci/mg, and was indistinguishable from native thrombin by SDS-PAGE and by its ability to clot fibrinogen.
Binding of "25-labeled thrombin to fibrin. 125I-Labeled thrombin was added to citrated plasma (-100,000 cpm/ml), and 500 -l aliquots of plasma were then transferred to polypropylene Eppendorf tubes. Clots were formed around wire hooks as described above. After incubation for 60 min at 37°C the clots were removed and washed three times with 500-ul aliquots of TBS, and the incorporation of '25I-labeled thrombin was determined by counting the clots for radioactivity for (Fig. 3) . In contrast, no increase in the plasma FPA level occurs when plasma is incubated in the absence of a clot (Fig. 3) . To confirm that clotbound thrombin is responsible for the increase in the FPA levels, several control experiments were performed. First, this increase does not result from the release of trapped peptide since < 5 nM FPA is recovered when clots are incubated in buffer in place of plasma. Second, clot-bound thrombin is responsible for this activity since no FPA is generated when clots preincubated for 30 min at 370C in buffer containing 10 nM hirudin or 6 nM PPACK are washed and then incubated in plasma. Third, the amount of FPA generated by clot-bound thrombin is directly related to clot size (Table I) , consistent with the concept that thrombin binding is dependent on the amount of available fibrin. In addition, the amount of FPA generated by clot sonicates is approximately threefold higher than that produced by intact clots (Table I ). This finding suggests that only thrombin bound to the surface of intact clots is available to interact with fibrinogen, whereas additional thrombin is exposed in the clot sonicates.
Incubation of clot sonicates with citrated plasma results in progressive FPA generation with a time course similar to that produced by the intact clots (data not shown). These findings suggest that thrombin that remains bound to clot fragments is also protected from fluid-phase antiproteinases.
Comparison of the activity of thrombin inhibitors against fluid-phase and clot-bound thrombin. To determine the ability ofthrombin inhibitors to inactivate thrombin bound to fibrin, clots were incubated in plasma in the presence or absence of the various agents and FPA release was quantified. These results were then compared with the activity of the thrombin inhibitors against FPA generated by fluid-phase thrombin. PPACK (Fig. 4) and hirugen ( Fig. 5 ) are equally effective inhibitors of fluid-phase and clot-bound thrombin because they block FPA release mediated by free thrombin and by the clotbound enzyme to a similar extent. Hirudin is slightly less active against solid-phase thrombin than it is against the fluidphase enzyme since each concentration of this agent inhibits the activity of clot-bound thrombin 50% less than the fluidphase enzyme (Fig. 6 ). In contrast, heparin is much less effective at inhibiting thrombin bound to fibrin (Fig. 7) . For example, 0.1 U/ml of heparin produces 70% inhibition of FPA release mediated by fluid-phase thrombin but has almost no activity against the clot-bound enzyme. Although heparin concentrations of 0.2-0.4 U/ml, which span the therapeutic Hirugen (jzM) range for this agent (30) , completely inhibit FPA release mediated by free thrombin, they produce only 20-40% inhibition of clot-bound FPA generation. Similarly, a concentration of 1 U/ml, which may be achieved after 5,000 U ofheparin is given as a bolus to patients (31) , inhibits the activity of clot-bound thrombin by only 60%. Increased inhibition is produced by higher concentrations of heparin, and a concentration of 2 U/ml produces 70% inhibition, an amount equivalent to the inhibition of fluid-phase thrombin effected by a concentration of heparin of 0.1 U/ml.
Inability of thrombin inhibitors to displace )25SIlabeled thrombin bound to fibrin. To directly monitor thrombin binding to fibrin we measured the incorporation of '251-labeled thrombin into clots. After aging the clots for 60 min and washing them thoroughly to remove trapped thrombin, 29.2±3.5% of the labeled enzyme was bound to fibrin. Despite 18 h of extensive washing at 23°C, 10.4±1.8% of the '251-labeled thrombin remained bound to fibrin. The ability of the various thrombin inhibitors to displace bound thrombin was then tested. Using each of the inhibitors at the concentration that produced 70% inhibition of FPA generation by clotbound thrombin (i.e., 2.0 U/ml heparin, 7.1 nM hirudin, 1 MAM hirugen, and 3 nM PPACK), displacement of 1251-labeled enzyme bound to the clot was not observed.
Discussion
These studies confirm previous reports that thrombin bound to fibrin is enzymatically active (2-7) and is protected from inhibition by heparin-antithrombin III (12) . However, we have extended these observations in a number of important ways. First, we have demonstrated that clot-bound thrombin is capable of releasing FPA from fibrinogen despite the presence of physiologic concentrations of antiproteinases (Fig. 3) since our studies were done in plasma and not in a buffer system. Second, we have shown that thrombin bound to fibrin polymer is relatively protected from heparin inactivation (Fig. 7) . The use of plasma-derived clots rather than artificially produced fibrin monomer (12) models more closely the physiologic events that occur during the coagulation process. Third, we have compared the susceptibility to inactivation of thrombin bound to fibrin with that of thrombin free in solution. These studies indicate that clot-bound thrombin is relatively protected from inactivation by heparin but is susceptible to inhibition by antithrombin III-independent inhibitors.
The thrombin inhibitors used in our study are heparin, hirudin, hirugen, and PPACK. These agents were chosen because they have different mechanisms of action. Heparin catalyzes thrombin inactivation by antithrombin III (8-1 1) , while the other thrombin inhibitors act independently of antithrombin III. Hirudin, a potent and specific inhibitor derived from Hirudo medicinalis, forms an essentially irreversible, stoichiometric complex with thrombin with a dissociation constant reported as low as 20 fM (32) . Recombinant forms of hirudin also have potent antithrombotic activity despite the fact that they are not sulfated at . Hirugen is a synthetic Tyr-sulfated dodecapeptide comprising residues 53-64 of the carboxy-terminal region of hirudin (19) . The antithrombin activity of hirugen appears to be the result of interaction with a noncatalytic site on thrombin, since hirugen blocks the fibrinogenolytic activity of the enzyme without affecting the amidolytic activity of thrombin against low molecular weight synthetic substrates (21) . In contrast, PPACK binds to the active site ofthrombin, wherein the active center histidine is irreversibly alkylated by the chloromethyl ketone (34) .
We compared the ability of these thrombin inhibitors to block fluid-phase thrombin with their activity against thrombin bound to fibrin. For both systems, plasma levels of FPA were used as an index of unoppored thrombin activity. The addition of a-thrombin to citrated plasma results in concentration-dependent generation of FPA (Fig. 1) . With each concentration of thrombin, FPA release reaches a plateau within minutes, consistent with rapid enzyme inhibition by plasma antithrombins. All of the thrombin inhibitors produce concentration-dependent inhibition of thrombin-mediated FPA release in plasma. Using the plasma system, we then identified concentrations of each agent that produce approximately equivalent inhibition of FPA release (Fig. 2) .
The time course of FPA generation by clot-bound thrombin (Fig. 3) is different from that produced by the fluid-phase enzyme (Fig. 1) . In the presence of a clot that has been thoroughly washed to remove trapped FPA and unbound thrombin, there is progressive FPA generation throughout the incubation period, indicating that clot-bound thrombin is enzymatically active and is protected from inactivation by plasma antiproteinases. Clots of increasing size generate more FPA (Table I) , presumably because the larger surface area exposes more thrombin to fibrinogen. Sonicates of washed clots generate approximately threefold more FPA than do intact clots, suggesting that fibrinogen in the surrounding plasma does not have free access to thrombin bound to fibrin in the interstices of the intact clot.
The ability of thrombin inhibitors to block FPA release mediated by fluid-phase thrombin was then compared with their activity against the clot-bound enzyme. Heparin is a relatively poor inhibitor of thrombin bound to fibrin since a concentration of heparin that inhibits -70% of thrombin-mediated FPA release has no effect on the activity of the clotbound enzyme (Fig. 7) . Instead, a 20-fold higher heparin concentration is required to produce equivalent inhibition of clot-induced FPA release (2.0 and 0.1 U/ml, respectively). Therefore, like thrombin bound to fibrin monomer (12), enzyme bound to a clot is also relatively protected from inactivation by heparin-antithrombin III. In contrast, PPACK and hirugen are equally effective inhibitors of fluid-and solidphase thrombin (Figs. 4 and 5, respectively). Hirudin is a slightly better inhibitor of the fluid-phase enzyme since each concentration of this agent produces twofold more inhibition of free thrombin than of the clot-bound enzyme (Fig. 6 ). These findings suggest that clot-bound thrombin may be readily accessible to low molecular weight inhibitors such as hirugen and PPACK (1,578 and 524 D, respectively), and less susceptible to inhibition by the 7,000-D hirudin molecule.
To explore the mechanism by which thrombin bound to fibrin is protected from inhibition by heparin-antithrombin III but susceptible to inactivation by antithrombin III-independent inhibitors, we examined the ability of the various agents to displace '25M-labeled thrombin from the clot. When used at concentrations that blocked 70% of clot-induced FPA generation (i.e., 0.1 U/ml heparin, 1.4 nM hirudin, 1.9 gM hirugen, and 3.0 nM PPACK), none ofthe inhibitors displaced fibrin-bound thrombin into the surrounding medium. PPACK, which blocks the active center histidine of thrombin (34), would not be expected to displace thrombin since the enzyme binds to fibrin through a site distinct from its catalytic center (2-7). Hirudin binds to two sites on thrombin during the formation of the enzyme-inhibitor complex. One is a low affinity site that does not impair thrombin-catalyzed hydrolysis of low molecular weight substrates, while the other is a high affinity site near the catalytic center of the enzyme (32) . Hirugen is an analogue of the carboxy-terminal region of hirudin. Its antithrombin effect is thought to be the result of hirugen interaction with the noncatalytic fibrinogen binding site on thrombin (21) . The experiments with '25I-labeled thrombin suggest that inhibition of clot-bound thrombin by hirugen and hirudin does not depend on enzyme displacement from its fibrin binding site.
Other investigators have demonstrated that hirudin can displace thrombin that is bound to fibrin monomer-Sepharose (4, 6). Our results are not necessarily incompatible with these findings since we investigated the displacement of thrombin bound to fibrin clots rather than to fibrin monomer. In addition, we used concentrations of hirudin that effectively block Clot-bound Thrombin Is Protectedfrom Inhibition by Heparin 389 FPA generation by clot-bound thrombin. Although these concentrations of hirudin do not displace the enzyme from fibrin, they are -400-fold lower than the concentrations necessary to displace thrombin from fibrin monomer-Sepharose (4, 6).
Heparin acts as an anticoagulant principally by catalyzing antithrombin III-mediated inactivation of thrombin (8) (9) (10) (11) . To accomplish this, heparin acts as a template and binds to both thrombin and antithrombin III (10, 11) . Recent studies in buffer systems have demonstrated that thrombin bound to fibrin monomer is protected from inactivation by heparin-antithrombin III (I12). Our findings are consistent with these observations, and demonstrate that thrombin bound to fibrin clots is relatively protected from inhibition by heparin-antithrombin III in a plasma system. In addition, it is likely that the heparin binding site on thrombin is inaccessible when the enzyme is bound to fibrin, since concentrations of heparin that produce 70% inhibition of FPA release mediated by fluidphase thrombin do not inhibit the clot-bound enzyme. A recent study by Mirshahi et al. (35) suggests that thrombin bound to fibrin degradation products also may be relatively protected from inactivation by heparin since enzyme released from the clot during pharmacologically induced fibrinolysis is more susceptible to inactivation by hirudin than by heparin.
Although heparin has proven to be an extremely effective antithrombotic agent, both experimental and clinical studies indicate that it is limited in its ability to inhibit the propagation of venous thrombi (14) (15) (16) (17) (18) or to prevent coronary rethrombosis after thrombolytic therapy (19, 20) . The studies presented here provide a plausible explanation for these limitations. Further, they raise the possibility that antithrombin IIIindependent inhibitors may be more effective than heparin in these clinical settings.
